Tareq Abadl: CMV and Transfusion – Leukoreduction vs CMV-Seronegative
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“CMV and Transfusion — Leukoreduction vs CMV-Seronegative
Cytomegalovirus (CMV) can be transmitted through blood components, but modern transfusion practice has reduced this risk dramatically.
For most at-risk patients, pre-storage leukoreduced (‘CMV-safe’) components are considered an effective alternative to routinely using CMV-seronegative units — with a few important exceptions.
What Major Authorities Say?
Organizations such as the AABB, the Centers for Disease Control and Prevention (CDC), and national blood services like Canadian Blood Services recognize that:
- Pre-storage leukoreduction significantly reduces transfusion-transmitted CMV (TT-CMV).
- Many programs consider leukoreduced (CMV-safe) and CMV-seronegative components clinically equivalent for most indications.
Important Exceptions
Maximal prevention is still recommended in certain high-risk settings:
- Intrauterine transfusion (IUT)
- Some extremely low-birthweight neonates
Selected transplant or severely immunocompromised patients (based on local policy)
- In these cases, request CMV-seronegative units in addition to leukoreduction.
- Always follow your institution’s policy and consult neonatology/transplant teams when needed.
Practical Blood Bank Guidance
Default practice:
Provide pre-storage leukoreduced components for routine transfusion.
For listed exceptions:
Request CMV-seronegative units plus leukoreduction.
Document the clinical indication clearly in the order.
System optimization:
Tag ‘CMV-safe’ components automatically in the LIS.
Add a required checkbox for ‘CMV-seronegative requested’ with documented reason.
Audit compliance and outcomes periodically.
Why Leukoreduction Works?
CMV resides mainly in white blood cells.
Leukoreduction removes the majority of this cellular reservoir, dramatically lowering TT-CMV risk.
That’s why many blood services shifted away from maintaining large universal seronegative inventories — it simplifies logistics while remaining protective for most patients.
Summary
- Leukoreduction: effective protection for most patients
- CMV-seronegative units: reserved for specific high-risk scenarios
- Always align practice with local policy and patient risk profile
Modern transfusion medicine balances safety, practicality, and evidence — not tradition.”
Find more posts featuring Tareq Abadl on Hemostasis Today.
-
Apr 15, 2026, 18:45Elias Lee: Acute PE from Subclavian VT – CT Scan Diagnosis, Radiology Interpretation, and Emergency Imaging Insights
-
Apr 15, 2026, 17:30Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health
-
Apr 15, 2026, 17:01Emmanuel J Favaloro: A Practical Approach to Inherited and Acquired Coagulation Disorders
-
Apr 15, 2026, 16:55Chokri Ben Lamine: VA-ECMO vs VV-ECMO Thromboembolic Events – Key Clinical Pearls
-
Apr 15, 2026, 16:54Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory
-
Apr 15, 2026, 16:53Sickle Cell Disease Care Varies by Region – ASH
-
Apr 15, 2026, 16:40Jorge Lima։ Understanding Recurrent Pregnancy Loss
-
Apr 15, 2026, 16:26Pregnancy-Induced Rise in FIX Activity – A Challenge to International Hemophilia Guidelines – JTH
-
Apr 15, 2026, 16:18Ken Checicki: How Restoring Blood Flow Can Solve Post – DVT Complications